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Bone is a specialized connective tissue with a calcified extracellular matrix in which cells are embedded. 
Besides providing the internal support of the body and protection for vital organs, bone also has several 
important metabolic functions, especially in mineral homeostasis. Far from being a passive tissue, it is 
continuously being resorbed and formed again throughout life, by a process known as bone remodeling. 
Bone development and remodeling are influenced by many factors, some of which may be modifiable in 
the early steps of life. Several studies have shown that environmental factors in uterus and in infancy may 
modify the skeletal growth pattern, influencing the risk of bone disease in later life. On the other hand, 
bone remodeling is a highly orchestrated multicellular process that requires the sequential and balanced 
events of osteoclast-mediated bone resorption and osteoblast-mediated bone formation. These processes 
are accompanied by specific gene expression patterns which are responsible for the differentiation of the 
mesenchymal and hematopoietic precursors of osteoblasts and osteoclasts, respectively, and the activity 
of differentiated bone cells. This review summarizes the current understanding of how epigenetic 
















































The social and public health measures implemented in the last century in developed countries have 
decreased the societal impact of communicable and other acute diseases to a great extent. Therefore, 
chronic disorders represent nowadays a major component of disease burden. Many of them belong to the 
group of the so-called “complex disorders”, which includes many prevalent disorders that are the final 
result of complex interactions of environmental and other acquired factors with genetic factors. 
Osteoporosis and osteoarthritis are the most prevalent skeletal disorders. In particular, osteoporosis has 
been estimated to affect about 30% of women and 12% of men above 50 years of age [1]. Osteoporosis is 
characterized by low bone mass and microarchitectural changes of bone tissue that result in a decreased 
bone resistance and susceptibility to fracture. Fractures in osteoporotic patients thus occur after low-
impact trauma in the peripheral skeleton, particularly at the hip, the wrist and the humerus. Vertebral 
fractures are also very common and may appear even without any trauma, just as a consequence of the 
daily activities.  
Osteoporosis is considered as a complex disorder. On the one hand, several acquired factors have been 
shown to be associated with decreased bone mass and/or increased risk of fractures, including low body 
weight, heavy alcohol and tobacco consumption, immobilization, corticoid use, etc. Nutritional factors are 
also important. Although some discrepant studies have been published, most researchers and clinicians 
agree that protein-energy malnutrition, low calcium intake and an inadequate supply of vitamin D 
increase the risk of osteoporosis. On the other hand, many epidemiological studies have provided strong 
evidence for a role of heredity in osteoporosis. In fact genetic factors have been estimated to account for 
40-80% of bone mineral density (BMD) variance [2-4]. Although fractures depend not only on the 
intrinsic properties of bone, but also on other personal and environmental factors, including the 
propensity to fall, a hereditary component of fractures has also been demonstrated. Thus, in the Study of 
Osteoporosis Fractures, a maternal history of hip fracture doubled the risk of fracture and the increase in 
risk remained significant after adjustment for bone density [5]. In a meta-analysis of several cohorts, 
Kanis et al. estimated that a family history of hip fracture in parents increased the risk of hip fracture 
(relative risk 2.3) and all osteoporotic fractures (relative risk 1.5) [6].  
BMD changes trough the life time of an individual. It accumulates during the growth period, reaches a 
peak by the third decade of life and then remains stable for some time. In later years, BMD begins to 
decrease progressively with aging. Therefore, osteoporosis may result from an inadequate peak bone mass 
attained in the early adulthood, from an accelerated loss of bone thereafter, or from a combination of 
both. The relative importance of peak bone mass and later losses on the development of osteoporosis 
probably varies among individuals, but the former is likely to be the most important. In fact, a 10% 
increase in peak BMD is predicted to delay the development of osteoporosis by 13 years, while a 10% 
change in the age at menopause or the rate of post-menopausal bone loss is predicted to delay 
osteoporosis by approximately 2 years, suggesting that peak BMD may be the single most important 
factor in the development of osteoporosis [7]. 
Theoretically, it could be anticipated that genetic factors have a more important influence on BMD in 
young individuals than in the elderly, as the relative contribution of environmental factors is likely 
stronger in the latter. Some studies support this notion. For example, Brown et al. studied 570 women 
from large Amish families and estimated that genes explained 58-88% of total variation in BMD in 
premenopausal women and 37-54% in the postmenopausal ones [8]. Likewise, in a twin study in Sweden, 
Michaelsson [9]  estimated a greater heritability for hip fractures before the age of 69 years (0.68; 95% 
CI, 0.41-0.78) and between 69 and 79 years (0.47; 95% CI, 0.04-0.62) than for hip fractures after 79 years 
of age (0.03; 95% CI, 0.00-0.26).  
From the studies mentioned above, and many others, the importance of genetic factors in osteoporosis is 
out of doubt. Some rare cases of osteoporosis due to single-gene mutations have been identified. They 
include mutations of the lipoprotein receptor related protein 5 (LRP5), collagen, aromatase and estrogen 
receptor genes [10]. However, most cases appear to be polygenic in nature, with multiple genes involved, 
each one having only a modest influence on the phenotype. In the past 15 years many linkage and 
association studies have been performed trying to identify the genes actually involved. Indeed, association 
signals have been reported and successfully replicated at various loci, using candidate gene or, more 
recently, genome-wide approaches.  
However, as it is the case for other complex disorders, these studies have been somewhat disappointing 
because the combination of all the gene variants identified explains only a very small fraction of the 
disease risk. This suggest that, at the cellular level, those genetic variants have only a modest impact on 
gene expression [11]. The reasons explaining the missing heritability are disputed, but they are likely to 
include complex gene-gene and gene-environmental interactions. Indeed, as already mentioned, some 
environmental influences are well recognized risk factors for osteoporosis. Since the genome is highly 
stable, in general environmental factors influence genome activity by mechanisms that do not involve 
DNA sequence modifications. Some of them may represent epigenetic mechanisms, which are heritable 
through generations or cell divisions. Thus, the epigenome of an individual is currently seen as the result 
of genetic factors, environmental influences and stochastic variations.  
There are still very scarce data about the actual role of epigenetic mechanisms in bone disorders. 
However, several emerging lines of evidence suggest that they may be important in the biology of bone 




Epigenetic regulation of gene expression 
  
The group of well-known epigenetic mechanisms include DNA methylation, chromatin (in particular, 
histone) modifications and miRNAs [12]. However, the group is likely to be expanded in the future. For 
instance, the roles for hydroxymethylcytosine residues and CpG island shores have been recently 
proposed [13;14]. Among epigenetic mechanisms, DNA methylation and histone modification modulate 
gene transcription, whereas miRNAs act at the post-transcriptional level. The most widely studied 
epigenetic mark is DNA methylation, whose role in tumurogenesis has been clearly established. In 
humans DNA methylation consists in the addition of a methyl group in cytosines that precede guanines 
(CpGs), process catalyzed by DNA methyl transferases, using S-adenosyl-methionine as donor of methyl 
groups [15]. Interestingly, there are CpG-enriched areas in many gene promoters and their surrounding 
regions, known as CpG islands [16]. DNA methylation at these sites is usually associated with silencing 
of gene transcription. The exact mechanisms by which DNA methylation marks inhibit gene transcription 
are not fully understood yet. However, some data suggest that it can directly impair the binding of 
essential transcriptional factors to their target sites.  
Histone modifications, including methylation, acetylation, phosporilation, SUMOylation and 
ubiquitination have been also largely studied [17;18]. The complexity of the histone tail modifications 
depends not only on the type of chemical groups added, but also on the aminoacid residue modified and 
the number of groups added. For example methylation may be in three different forms: mono-, di-, or 
trimethyl for lysines and mono- or di- (asymmetric or symmetric) for arginines [17]. In general, histone 
modifications can be divided into those that correlate with activation of transcription (mainly acetylation 
and phosphorilation) and those that correlate with repression (methylation, ubiquitination and 
sumoylation) [19].The term “histone code” is frequently used to describe a specific set of modifications 
for a given task.   
The first miRNA were discovered in the early 90s [20] and their number is still growing. miRNAs are non 
coding RNAs of about 22 nucleotides. Approximately 1500 different miRNA have been identified in 
humans so far, and the number will probably increase in the future years [21]. Interestingly, bioinformatic 
predictions indicate that miRNAs may be involved in the regulation of 60% of the coding genes [22]. 
These small RNAs are initially transcribed as long primary transcripts, and then undergo  specific 
cleavage driven by the Drosha and Dicer enzymes. The mature miRNA loss one strand, whereas the 
other, know as the complementary miRNA strand, is loaded into the RISC protein complex, which 
mediates the effect on gene expression [23]. miRNAs bind to the 3´or 5´UTR of messenger RNAs  and 
induce mRNA cleavage or translational repression, depending on the degree of complementarity [24]. 
When there is extensive complementarity, RISC mediates the cleavage of the target mRNA, whereas in 
case of loose complementarity the complex will impair the advance of the ribosome complex repressing 
translation.  
Although each mechanism by itself is capable of affecting gene expression, they also interact with each 
other in a cooperative manner, allowing the cells to activate or repress gene expression in a time and 
tissue-specific manner. It has been shown that DNA methylation and histone posttranslational 
modifications contribute to the establishment and maintenance of chromatin accessibility [25].  Indeed, 
methyl-CpG biding proteins, which recognize methylated CpGs, recruit HDACs to methylated DNA, 
promoting the gain of repressive marks in the histone tails [26]. Likewise, miRNAs may also influence 
DNA methylation or chromatin remodeling [27]. Furthermore, it has been recently suggested that the 
expression of certain miRNAs may be controlled by  CpG methylation and histone modification  [28;29]. 
 
 
The complex processes of bone formation and bone remodeling 
 
Bone tissue consists in a heavily mineralized extracellular matrix, with collagen as the major protein 
component, and different cell types. Far from being a static organ, bone changes in structure and 
composition from birth to adulthood. Modeling and remodeling are the processes by which bone adapts to 
external influences. Bone modeling is responsible for the gain in skeletal mass and the changes in skeletal 
size and shape taking place during the growth period, whereas bone remodeling replaces old bone by new 
bone tissue, throughout life, and specifically in the adult skeleton, to maintain bone mass, repair bone 
microfractures and allow the adaptation to external physical requirements [30].  
The most important cells in bone homeostasis belong to two separate families: the osteoclastic and the 
osteoblastic lineages. Osteoclasts derive from hematopoietic precursors and are responsible for bone 
resorption. On the other hand, osteoblasts derive from local mesenchymal precursors and are responsible 
for bone formation. There are several types of cells within the osteoblastic lineage, with different gene 
repertoires, shapes and functions. The bone forming osteoblasts are cuboidal cells that synthesize alkaline 
phosphatase, collagen and other constituents of the bone matrix. The osteocytes are stellated cells that 
derive from osteoblasts that become embedded in the cell matrix they have formed. Finally, the so-called 
lining cells are flat-shaped cells that cover the inactive bone surfaces. However, cells in the osteoblastic 
lineage not only form bone, but have other roles in bone metabolism. They modulate the proliferation and 
differentiation of osteoclast precursors, and regulate osteoclast activity [31;32]. 
During bone modeling, resorption and bone formation occur on separates surfaces, whereas during 
remodeling, formation and resorption are coupled. The process of bone remodeling begins when a group 
of osteoclasts resorb a small volume of bone tissue (Figure 1). When this phase finishes, osteoblasts 
arrive to the area and fill with new bone the cavity eroded by osteoclasts. Therefore, the processes of bone 
resorption and bone formation are critical determinants of bone mass and strength. In fact, the decreased 
bone mass that characterizes osteoporosis at the tissue level represents the consequence of an imbalance 
between osteoclast and osteoblast function at the cellular level [33;34]. 
Maintaining skeletal properties and functionality depends on the organized action of all cell types present 
in this tissue. In fact, there are complex interaction networks between osteoblasts, osteoclasts and 
osteocytes. In particular, osteocytes are emerging as critical elements in the regulation of skeletal 
homeostasis. They may act as mechanosensors, mark the sites where a remodeling cycle must be initiated 
and secrete a number of factors that influence the activity of other cells in the osteoblastic as well as the 
osteoclastic lineages [35]. This interplay between cells promotes changes of the expression level of target 
genes, resulting in variations of cell activity. In addition, since bone remodeling takes place in a time and 
site-coordinated way, the differentiation of osteoblast and osteoclast precursors must also be controlled in 
a time and site-specific manner. The differentiation programs of these cells promote marked changes in 
gene expression, translated into different morphologies and activities, thus allowing the mature cells to 
achieve its expected function. Therefore, mechanisms regulating the transcriptional activity of those 
genes play a critical role in bone homeostasis and bone disease. 
 
Epigenetic marks in the osteoblastic lineage differentiation 
 
Osteoblasts and osteocytes originate from mesenchymal stem cells (MSCs). Interestingly, not only bone 
cells derive from these precursors, but also adipocytes and myogenic cells, as well as chondrocytes, share 
the same progenitor [36]. This highlights the need for mechanisms regulating lineage-specific 
differentiation of MSCs and then maintaining the mature phenotypes. Regarding the bone tissue, MSCs 
differentiate into osteoblasts and these will eventually evolve into osteocytes and lining cells, through a 
complex process that involves transcription factors and also modifications of the epigenetic marks (Figure 
2) [37;38]. During osteogenic differentiation, MSCs undergo a dramatic transformation, at gene 
expression, functional and morphological levels [39]. Thus, cell shape changes from the polygonal bone 
forming osteoblasts to the dendrite-rich stellate osteocytes The podoplanin gene appears to be involved in 
this process, and its expression may be regulated by a cooperative crosstalk between DNA methylation 
and histone modification in osteoblastic cells [40]. On the other hand, the change in cell shape between 
bone forming osteoblasts and osteocytes is accompanied by different gene expression profiles. It is known 
that alkaline phosphatase activity, an enzyme critical for bone mineralization, is high in osteoblasts, the 
unique bone forming cell, whereas it is reduced in osteocytes, which do not produce bone [41]. In line 
with this, we recently demonstrated that osteoblasts and osteocytes have opposite DNA methylation 
profiles in the alkaline phosphatase (ALPL) promoter, which is hypomethylated in osteoblasts and 
hypermethylated in osteocytes, suggesting that DNA methylation is inhibiting ALPL expression in the 
latter [42]. The opposite is the case of SOST, which is actively expressed in osteocytes, but not in 
osteoblasts [39]. SOST is the gene encoding sclerostin, a peptide that tends to impair osteoblast activity 
by inhibiting Wnt signaling [43]. We have recently demonstrated that DNA methylation may be 
responsible for the repression of SOST expression in osteoblasts. Furthermore, we observed that DNA 
demethylation occur during osteoblast-osteocyte transition, allowing osteocytes to express SOST [44]. In 
addition, Cohen-Kfir et al. suggested that sirtuin 1, a histone deacetylase, directly regulates SOST 
expression [45].  
It has been shown that DNA demethylation induced by chemical compounds facilitates osteogenic gene 
expression and differentiation [46]. Likewise, it has been reported that reduced DNA methylation of other 
CpG islands in the promoter regions of osteocalcin (BGLAP) and osteopontin genes is associated with 
osteogenic differentiation [47;48]. On the other hand, high DNA methylation at the promoter of 
Brachyury transcription factor may be required for this process [49]. Other genes influencing 
osteogenesis, such as osterix, the osteogenic protein Dlx-5, aromatase and the estrogen receptor are also 
regulated by DNA methylation [50-53]. Not only DNA methylation is critical for osteogenic 
differentiation, but also chromatin remodeling plays an important role. It has been shown that different 
transcription factors induce chromatin remodeling at target promoters [54]. In fact, histone modifications 
are associated with BGLAP expression [55]. H3K4 and H3K6 methylation is associated with HOXa-10 
and AP-2α expression respectively, and determine the advance of the osteogenic differentiation [56;57]. 
Other important genes regulated by histone modifications are Runx2, AP-1, ATF4 and Smads [58].  
The analysis of miRNA arrays have identified several miRNAs whose expression changes during MSC 
differentiation, affecting  target gene translation [59], and thus suggesting that miRNAs expression is 
actively involved in the regulation of this process (table 1). It has been shown that miRNAs regulate the 
expression of pivotal osteogenic transcription factors, such as Runx2 or Smads. Runx2 is required for 
determination of the osteoblast lineage. This transcription factor induces the differentiation of multipotent 
MSCs into immature osteoblasts modulating the expression of key genes during the early stages of 
osteoblast differentiation, such us collagen type 1 and 2, BGLAP, fibronectin, sclerostin or 
osteoprotegerin [60;61]. miR-204 and its homologue miR-211, as well as miR-133 and miR-135b, inhibit 
Runx2 [62-64]. On its turn, Runx2 may also regulate the expression of some miRNAs involved in the 
osteogenic process [65]. 
miRNAs are actively involved in the regulation of Smad protein levels. Smads are intracellular proteins 
that transmit signals originating from the interaction of bone morphogenetic proteins (BMPs) and 
transforming growth factors (TGFs) with their receptors at the cell membrane. It is know that BMP/TGF 
and Runx2 pathways converge for the transcriptional control of bone formation. Thus, Smad proteins are 
recruited to Runx2 regulatory complexes and collaborate to modulate gene expression [66]. miR-26a has 
been shown to negatively regulate Smad1, resulting in a decreased expression of various bone markers, 
such as ALPL, BGLAP, osteopontin, and COL2A1 [67]. miR-135 regulates other member of the Smad 
family, Smad5 [64]. miR-141 and miR-200a, through Homebox Distal-Less-5 (Dlx5) decreased the 
expression, among others, of BMP-2 [68]. Recent studies demonstrated that miR-206 inhibit connexin 43 
expression and tend to impair osteoblast differentiation [69]. The miR-23a ~ 27a ~ 24-2 complex inhibits 
osteoblastogenesis by negative regulation of SATB2 [65]. miR-29a and miR-29c are involved in the 
regulation of Wnt pathway and inhibit the expression of osteonectin [70]. Finally, miR-125b inhibits Erb-
2 and negatively regulates osteoblast proliferation [71].  
Contrary to the negative role of various miRNAs, it has been described that some miRNAs promote 
osteogenesis. miR-29b, miR208 and miR-210 modulate BMP/TGF/Activin signaling [72]. miR-218 
negatively regulates Erb1 (TOB1) and sclerostin (SOST) [73]. miR-196 targets Hoxc8 (a Smad1 negative 
regulator) impairing adipogenesis and promoting osteogenesis [74]. Finally, miR-335-5p attenuates Dkk1, 
an inhibitor of the Wnt pathway, and consequently increase Wnt pathway activity and tends to facilitate 
osteoblast formation [75]. The exact role of these mechanisms in the pathogenesis of bone disorders 
remains to be elucidated. Nevertheless, whether they are involved in skeletal disorders or not, those 
studies suggest that the modulation of epigenetic mechanisms may be used to improve bone tissue 
engineering and in general in bone regenerative medicine, specifically when there is a need to form new 
bone to heal a local skeletal defect. 
 
Epigenetic changes during osteoclastogenesis: control of remodeling  
 
Activation of osteoclastogenesis is required for remodeling. Although not definitively proved in humans, 
some experimental data suggest that osteocytes start the cascade of events for osteoclast differentiation, 
presumably releasing cytokines and other factors that modulate the activity and differentiation of cells in 
both the osteoblastic and osteoclastic lineages [35;39]. On the other hand, there is extensive evidence for 
a role of cells of the osteoblastic lineage in the regulation of osteoclastogenesis. In fact, different 
molecules produced by osteoblastic cells, including stromal derived factor (SDF), the monocyte 
chemotactic protein type 1 (MCP-1) or the macrophage colony-stimulating factor (M-CSF), have been 
shown to either attract osteoclast precursors to the sites of bone remodeling or stimulate their proliferation 
[76-78]. Other critical factor in osteoclastogenesis is the Receptor activator of nuclear factor Kappa-B 
ligand (RANKL) which initiates the cascade of events for osteoclast maturation. RANKL is produced by 
many cell types, such as immune, vascular and stromal cells. However, it is well accepted that osteoblasts 
and probably osteocytes, are the major sources of this cytokine in bone tissue. Interestingly, Kitazawa et 
al. demonstrated that DNA methylation at the proximal promoter of the RANKL gene inhibits its 
expression in a murine system, which results in impaired osteoclastogenesis [79]. Our group has recently 
reported a similar regulation of RANKL expression by the methylation/demethylation of a CpG island 
located in the vicinity of the RANKL promoter in human cells [80].  
RANKL acts by binding to its receptor RANK located in the membrane of osteoclast precursors [81;82]. 
This induces a cascade of molecular events that leads to the activation and nuclear translocation of the 
nuclear factor of activated T cells (NFATc1) [83] which, in turn, induces the expression of a variety of 
target genes, thus promoting osteoclast differentiation. Recent reports suggest that NFATc1 activity may 
be controlled by Jumonji, a histone demethylase, as well as by miR-146a [84;85].  
It is important to note that osteoblasts also synthesize and secrete osteoprotegerin (OPG), a soluble decoy 
receptor of RANKL that inhibits its interaction with RANK [86;87]. Together with RANKL and RANK, 
these three factors constitute the RANKL-RANK-OPG system. The RANKL/OPG balance at the bone 
microenvironment is considered a major determinant of bone mass. Indeed, RANKL and RANK 
knockout mice show a marked increase in bone mass, mainly due to a decrease in osteoclast numbers, 
whereas OPG knockout mice show the opposite phenotype [88-90]. Therefore a precise control of the 
expression of these genes is required for normal bone homeostasis, as well as for bone adaptation to 
environmental factors. Not only RANKL and NFATc1, but also other genes related to this signaling 
system are epigenetically regulated (Figure 3). Indeed, it has been shown that DNA methylation and 
histone modifications cooperate to regulate OPG expression in nasopharyngeal carcinoma tumors [91]. 
Data from our laboratory suggest that the methylation of CpG-rich regions in the OPG gene may also 
regulate OPG levels in human osteoblastic cells and non-neoplastic bone tissue [80]. Furthermore, results 
from in vitro experiments using histone deacetylase inhibitors suggest that osteoclast activity is 
modulated by these enzymes [92].  
Besides DNA methylation and histone post-translational modifications, growing evidence supports the 
notion that osteoclastogenesis may be regulated by miRNAs, acting in both a positive and negative ways 
(Figure 3C). In support of this notion, it has been shown that specific ablation of the Dicer enzyme in 
osteoclastic cells suppresses bone resorption [93]. Additionally, over-expression of miR-223 inhibits 
osteoclastogenesis [94], whereas, on the contrary, two miRNAs, miR-21 and miR-155, have been 
reported to exert a permissive role on osteoclast differentiation, decreasing the levels of some inhibitory 
genes [95;96]. As an obvious consequence of those studies, it is tempting to speculate that the inhibition 
of miRNA facilitating osteoclastogenesis might represent an attractive new approach to treat disorders 
characterized by an accelerated bone resorption. Interestingly, it has been suggested that not only 
osteoblasts regulate osteoclast activity, but osteoclasts may also, in turn, influence osteoblast 
differentiation. Several mechanisms may be involved, including changes in the expression levels of some 
miRNAs [97].  
 
The role of epigenetic marks in Osteoporosis 
 
The role of epigenetics in osteoporosis is just starting to be studied. However, it is gradually being 
postulated as a key concept, because epigenetic mechanisms are involved in the interactions between the 
genome and the environment, and, on the other hand, they drive the differentiation programs for cell fate, 
which, as already mentioned, play a critical role in remodeling of bone tissue. Although the exact 
relationship between epigenotypes and disease phenotypes is still to be elucidated, it is known that 
epigenetic marks change during aging, including a global decrease in the abundance of 5- 
methylcytosines and some histone modifications [98]. Since osteoporosis is an age-related disease, it 
could be speculated that those age-related changes in epigenetic marks participate in the pathophysiology 
of the disease. However, at the present time this remains merely speculative. 
There is evidence that the environment has a strong influence on bone mass, even during the gestation 
period. Indeed, the intra-uterus environment has been shown to affect the development of the fetal 
skeleton with effects not only evident at birth, but also persisting later in life (recently reviewed by 
Holroyd et al.) [99]. For instance, the velocity of fetal femur length growth has been associated with the 
skeletal size at 4 years of age [100]. Maternal factors that have been associated with neonatal bone mass 
include body weight, fat stores, physical activity and smoking. Likewise, vitamin D and calcium 
availability during pregnancy have been shown to influence both fetal skeletal development and 
childhood bone mass [101]. Furthermore, poor growth in uterus and during the first years of life seems to 
be associated with thinner bones and the risk of fractures in the adulthood [102].  
Overall, these and other data strongly suggest that, besides genetic factors, environmental influences 
during the early phases of development and growth influence the peak bone mass, and consequently the 
risk of osteoporosis. The mechanisms involved remain to be elucidated, but some data indeed suggest that 
they may include epigenetic changes. Most data come from animal studies. For instance, feeding pregnant 
rats with a low protein diet resulted in a reduced bone mass in the offspring that persisted up to 75 weeks 
of age and was accompanied by an impaired proliferation and differentiation of bone marrow stromal 
cells, a population including osteoblast precursors [103;104]. It has been shown that maternal dietary 
restriction in rats induces changes in the methylation status of the genes coding for the glucocorticoid 
receptor and the peroxisomal proliferator-activated receptor alpha (PPAR) which persist after weaning 
and are transmitted to future generations [105-107]. There is also indirect evidence for an influence of 
early life conditions on the gene methylation status in humans. Thus, Dutch subjects exposed prenatally to 
famine in 1944 have been reported to have an increased risk of a variety of metabolic and neurological 
disorders, along an abnormal methylation status of various gene promoters, including IGF2 and other 
genes related to tissue growth and metabolism [108;109]. However, a direct proof of a link between in 
uterus environment, DNA methylation and bone mass in humans is not available yet.  
Besides DNA methylation, the roles of miRNAs and histone modifications in osteoporosis are being 
actively studied. In a recent report, three DNA polymorphisms have been found to alter the binding 
affinity of specific miRNAs that regulate the levels of the FGF2 gene and contribute to determine the 
susceptibility to osteoporosis [110]. A study by Li et al. represents an interesting example of interaction 
between two epigenetic mechanisms, miRNA and histone code. They  described a homozygous mutation 
in pre-miR-2861 that impaired the formation of the mature miRNA and caused a decrease of bone mass, 
mainly by targeting HDAC5 [111]. Eskildsen aet al. suggested that miR-138 could be involved in the 
reduced levels of the focal adhesion kinase gene observed in osteoporotic and osteoarthritic patients 
[112]. 
On the other hand, a decreased expression of heparanase (HPSE) has been observed in osteoblasts of 
osteoporotic patients, in comparison with those isolated from healthy individuals. HPSE is presumably 
involved in histone phosphorylation [113].  
Some drugs used or postulated as treatments for osteoporotic patients have been suggested to induce 
epigenetic changes. This is the case of the parathyroid hormone, which modulates histone deacetylase 
activity in osteoblasts [114]. Although not approved as an anti-osteoporotic drug, resveratrol, a 
polyphenolic phytoestrogen, has been shown to exhibit potent bone anti-catabolic properties, and 
presumably acts influencing the activity of sirtuin 1, an histone deacetylase [115]. Bisphosphonates are 
the most widely drugs used to treat osteoporotic patients. They are potent inhibitors of bone resorption by 
targeting the mevalonate pathway in the osteoclasts. Moreover, some data suggest that they may also have 
effects on bone formation. In line with this, it has been reported that bisphosphonates modulate the 
expression of some miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, that influence 
osteoblast proliferation [116]. Further studies are needed to elucidate whether it is central to 




As reviewed above, both epidemiological and experimental data suggest that epigenetic mechanisms 
influence skeletal development and the risk of bone disorders. Nevertheless, further research is required 
to elucidate the exact role of these mechanisms in the phenotypic changes responsible for skeletal 
diseases. In particular, the specific changes in DNA methylation, histone modifications and miRNA 
expression involved in the pathogenesis of osteoporosis remain to be identified. Although animal models 
provide a useful resource for the investigation of these mechanisms, so far it is unclear to what extent the 
results can be extrapolated to humans. Therefore, studies in human systems are of special interest.  
Genome-wide studies have identified a number of genes associated with bone mass. However, they only 
explain a small fraction of the bone mass variation observed in the population [117]. The explanations for 
this unexpected result are unclear, but may include the interaction between genetic and epigenetic 
mechanisms. In fact, epigenetic changes regulate gene transcription, but there is also growing evidence 
for an influence of genetic (i.e., DNA sequence) variants on DNA methylation and miRNA-dependent 
mechanisms (“genetical epigenomics”) [118]. 
New technologies such as epigenetic microarrays and ultra-high throughput sequencing may help to 
establish a complete epigenetic landscape of normal bone and skeletal diseases on a genome-wide basis.  
For instance, the comparison of cytosine methylation in subjects with different bone phenotypes may lead 
to the identification of differentially methylated regions involved in disease pathogenesis. It is worth 
mentioning that those studies present more difficulties than genome studies, due to the cell/tissue 
specificity of epigenetic marks and their instability over time. Since bone is a very heterogeneous tissue, 
composed of a variety of cells in bone itself and bone marrow, the results obtained in bone tissue samples 
may be hard to interpret. Nevertheless, the identification of disease-specific patterns of DNA methylation 
or miRNA expression may give valuable information. First, it may help to identify genes and metabolic 
pathways involved in the disease and consequently lead to discover new targets for disease therapy.  
On the other hand, the identification of disease-specific epigenetic marks may be helpful for both 
diagnosis and prevention. DNA, either methylated or unmethylated, and miRNA are more stable than 
RNA [119], which may be an advantage for clinical use. Of course, to this respect, markers in accessible 
samples, especially those present in circulating blood and body fluids, will be much more feasible to be 
used as diagnostic tools [120]. 
Studies of bone epigenetics may not only point to certain genes as new targets for therapy, but may 
represent the foundation of new therapies based on the control of epigenetic mechanisms. Some 
demethylating agents are already used to treat neoplastic disorders [121;122] . It would be interesting to 
study their effects on “bone genes”. However, their potential utility is limited by their widespread effects. 
Agents able to modulate specifically the epigenetic control of genes in a given pathway would be much 
more useful. In line with this, therapies based on small RNAs, mimicking or interfering with miRNAs, 
might be more specific and promising [123;124]. Both DNA-methylation- and miRNA-based treatments 
may be also useful in regenerative medicine. For instance, one could envision a future in which the 
demethylation of the promoters of certain genes driving osteoblast proliferation in a limited region of the 
skeleton might be used to fill bone defects and enhance the consolidation of delayed-union fractures. 
Another priority research line in this field may be the study of the potential influence of current therapies 
on the epigenetic regulation of bone factors. Of particular interest, the effect of anabolic agents, such as 
parathyroid hormone and bone morphogenetic proteins on the methylation of CpG-rich regions of genes 
involved in the regulation of bone remodeling should be investigated. If these drugs indeed modify DNA 
methylation patterns, prior knowledge of the patient methylation profile might help to individualize 
therapy according to his epigenome (“pharmacoepigenomics”). 
Overall, although data are still scarce, studies highlighted in this review invite to think that epigenetics 
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Figure 1.The bone remodeling cycle. The start of bone remodeling is probably driven by osteocytes 
(Stimulation). Osteoclasts are recruited to the bone surface by chemoatraction and remove a discrete 
packet of bone (Resorption). After a brief reversal phase in which osteoclast stop to resorbe bone and 
undergo apoptosis, osteoblasts arrive to the region and secrete bone matrix, filling the cavity (Formation). 
Note that some osteoblasts are buried within the new matrix, becoming osteocytes. The resorption phase 
last only a few weeks, whereas bone formation takes several months. Once the cavity is completely 
restored, bone enters the resting phase. 
 
Figure 2. The osteoblastic lineage differentiation. A complex network drives the osteogenic 
differentiation of the mesenchymal stem cells (MSCs). Transcription factor Runx2 controls the process 
inducing the expression of key genes. Its expression is tightly regulated by a wide variety of mechanisms, 
including positive and negative modulators, co- activators and co-repressors, as well as epigenetic marks. 
Likewise, some of these mechanisms are also epigenetically regulated.  
 
Figure 3. Mechanisms involved in the epigenetic regulation of osteoclastogenesis. A) DNA methylation at 
CpG-rich areas within the RANKL and OPG promoters blocks gene transcription, impairing 
osteoclastogenesis. B) Histone post-translational modifications have been shown to directly modulate 
NFATc1 activity and OPG transcription. C) miRNAs have both positive and negative effects on the 
progression of osteoclast precursor differentiation. miR-21 and miR-155 have a positive effect by 







































Table 1. Some studies identifying miRNAs involved in the regulation of osteoblast differentiation 
 
miR # ID Observation Ref. 
miR-125b Inhibits proliferation and impairs osteoblast 
differentiation 
[71] 
miR-133/135-a Target Runx2 and Smad 5, impairing osteoblast 
differentiation 
[64] 
miR-135b Targets sialoprotein, osterix, osteocalcin and Runx2 [63] 
miR-141/200a Target Dlx5, impairing osteoblast differentiation  [68] 
miR-196a Target Hoxc8, enhancing osteogenic differentiation [74] 
miR-204/211 Target Runx2 impairing osteoblast differentiation [62] 
miR-206 Targets connexin 43, impairs osteoblast differentiation [69] 
miR-208 Indirectly upregulates BMPs [125] 
miR-210 Targets AcvR1b, inducing osteogenesis. [126] 
miR-218 Decreases SOST and TOB1 expression [73] 
miR-23a/27a/24-2 Regulated by Runx2; target SATB2 and Runx2. [65] 
miR-26a Targets Smad1, impairing osteoblast differentiation [67] 
miR-2861 Targets HDAC5, inducing osteogenic differentiation [111] 
miR-29/29c Modulate Wnt pathway; target osteonectin [70] 
miR-29b Promotes osteogenic differentiation  [72] 
miR-30c/34c/133a/135a/137/204/205/217/338 Target Runx2 and impair osteoblast differentiation [127] 
miR-31/106a/148a/424/30c/15b Differentially expressed during MSC osteogenic 
differentiation  
[59] 
miR-335-5p Negative regulation of DKK1, increasing Wnt signaling [75] 
 
